AstraZeneca Invests $1.5 Billion in Singapore for Comprehensive Antibody-Drug Conjugate Manufacturing

1. AstraZeneca, a global biopharmaceutical company, has announced a significant investment of $1.5 billion in Singapore to establish end-to-end manufacturing capabilities for antibody-drug conjugates (ADCs).
2. The new facility will focus on the production of ADCs, a type of targeted cancer therapy that combines monoclonal antibodies with cytotoxic drugs to specifically target cancer cells, minimizing damage to healthy cells.
3. The investment will support AstraZeneca's growing portfolio of ADCs and enable the company to meet the increasing global demand for these innovative cancer treatments.
4. The Singapore facility will be AstraZeneca's first end-to-end ADC manufacturing site, covering all stages of production, from drug linking to sterile formulation and packaging.
5. The investment is expected to create numerous job opportunities in Singapore's biotechnology sector and further strengthen the country's position as a global hub for biopharmaceutical manufacturing.
6. AstraZeneca's decision to invest in Singapore is a testament to the country's robust infrastructure, skilled workforce, and supportive business environment for the biotechnology industry.
7. The new facility is scheduled to be operational by 2026, with the first ADC product expected to be manufactured in 2027.